Gepotidacin(Gepotidacin) - 药物靶点：Bacterial DNA gyrase x Bacterial top IV x Top II_在研适应症：细菌感染，泌尿道感染，急性膀胱炎_专利_临床

概要

基本信息

药物类型

小分子化药

别名

Gepotidacin (USAN/INN)、Gepotidacin Mesylate、GSK 2140944

+ [4]

靶点

Bacterial DNA gyrase x Bacterial top IV x Top II

作用方式

抑制剂

作用机制

Bacterial DNA gyrase 抑制剂(细菌DNA旋转酶抑制剂)、Bacterial top IV抑制剂(细菌拓扑异构酶IV抑制剂)、Top II抑制剂(拓扑异构酶II抑制剂)

治疗领域

在研适应症

非在研适应症

原研机构

在研机构

GlaxoSmithKline UK Ltd.

GSK PlcGlaxoSmithKline Trading Services Ltd.

+ [1]

非在研机构

葛兰素史克（中国）投资有限公司

Atos SE

权益机构-

最高研发阶段批准上市

首次获批日期

美国 (2025-03-25),

细菌感染泌尿道感染

最高研发阶段(中国)临床申请批准

特殊审评优先审评 (美国)

登录后查看时间轴

结构/序列

分子式C24H28N6O3

InChIKeyPZFAZQUREQIODZ-LJQANCHMSA-N

CAS号1075236-89-3

关联

24

项与 Gepotidacin 相关的临床试验

NCT06597344

/ Completed临床3期

A Phase 3b, Open-label, Single-arm Study in Adolescent and Adult Female Participants to Evaluate Clinical Symptom Improvement and the Safety of Gepotidacin During Treatment of Uncomplicated Urinary Tract Infections (Acute Cystitis)

The study will be conducted to evaluate the clinical symptom improvement and safety of oral gepotidacin for treatment of uncomplicated UTI (acute cystitis) in adolescent and adult female participants.

开始日期2024-10-02

申办/合作机构

GSK Plc

NCT05630833

/ Completed临床3期

A Phase III, Multicenter, Randomized, Active Reference, Double Blind, Double-dummy Study in Japanese Female Participants to Evaluate the Efficacy and Safety of Gepotidacin in the Treatment of Uncomplicated Urinary Tract Infection (Acute Cystitis)

The purpose of this study is to evaluate the consistency of therapeutic response of gepotidacin in female participants with acute uncomplicated cystitis with qualifying bacterial uropathogen(s) at baseline that all are susceptible to nitrofurantoin in Japan, with that from global studies (Studies 204989 [NCT04020341] and 212390 [NCT04187144]).

开始日期2023-01-11

申办/合作机构

GSK Plc

JPRN-jRCT2031220467

/ Not yet recruiting临床3期IIT

A Phase III, Multicenter, Randomized, Active Reference, Double-blind, Double-dummy Study in Japanese Female Participants to Evaluate the Efficacy and Safety of Gepotidacin in the Treatment of Uncomplicated Urinary Tract Infection (Acute Cystitis) - A study to investigate the efficacy and safety with gepotidacin in Japanese female participants with uncomplicated urinary tract infection (acute cystitis); Efficacy of Antibacterial Gepotidacin Evaluated in Japan (EAGLE-J)

开始日期2023-01-11

申办/合作机构-

100 项与 Gepotidacin 相关的临床结果

登录后查看更多信息

100 项与 Gepotidacin 相关的转化医学

登录后查看更多信息

100 项与 Gepotidacin 相关的专利（医药）

登录后查看更多信息

102

项与 Gepotidacin 相关的文献（医药）

2025-09-09·ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Efficacy and in vitro activity of gepotidacin against bacterial uropathogens, including drug-resistant phenotypes, in females with uncomplicated urinary tract infections: results from two global, pivotal, phase 3 trials (EAGLE-2 and EAGLE-3).

Article

作者: Breton, John ; Scangarella-Oman, Nicole E ; Janmohamed, Salim ; Kasapidis, Cara ; Brown, Derrek ; Millns, Helen ; Huang, Chun ; Perry, Caroline R ; Dennison, Jeremy ; Sheets, Amanda J ; Butler, Deborah L

Two recent Phase 3 trials demonstrated the efficacy of gepotidacin compared with nitrofurantoin to treat uncomplicated urinary tract infections (uUTIs) in females. Pretreatment urine specimens were obtained from all participants. Based on pooled trial data (treatment groups combined), central laboratory culture results identified 1,421 (45%) participants with ≥1 baseline qualifying (≥10⁵ CFU/mL) uropathogen (i.e., pooled microbiological Intent-to-Treat population). Escherichia coli, Klebsiella pneumoniae, and Proteus mirabilis were the most common qualifying uropathogens. Among 1,159 E. coli isolates, 28%, 28%, 15%, and 28% were fluoroquinolone resistant (FQ-R), trimethoprim-sulfamethoxazole resistant (SXT-R), extended-spectrum β-lactamase positive (ESBL+), and multidrug resistant (MDR), respectively. For 114 K. pneumoniae isolates, 25%, 23%, 16%, and 16% were nitrofurantoin resistant, SXT-R, FQ-R, and ESBL+, respectively. Of 67 P. mirabilis isolates, 25%, 21%, and 31% were SXT-R, FQ-R, and MDR, respectively. Gepotidacin MIC₉₀ values against all qualifying uropathogens and drug-resistant phenotypes ranged from 0.25 to 32 µg/mL, with no isolates of Enterobacterales, Staphylococcus saprophyticus, or Enterococcus faecalis considered resistant to gepotidacin. For all uropathogen drug-resistant phenotypes, gepotidacin MIC₉₀ values were similar (i.e., lower, equal to, or 1-dilution higher) compared with the MIC₉₀ of the overall species. Gepotidacin's efficacy, based on therapeutic, clinical, and microbiological success rates, was generally consistent across phenotypic subgroups of E. coli, K. pneumoniae, and P. mirabilis. This pooled analysis represents a robust, contemporary, clinically relevant, and unbiased (i.e., baseline urine specimens obtained from all enrolled participants regardless of uUTI history) collection of data from community-acquired uUTIs in females.CLINICAL TRIALSThis study is registered with ClinicalTrials.gov as NCT04020341 and NCT04187144.

2025-09-09·ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Efficacy and in vitro activity of gepotidacin against bacterial uropathogens, including subsets with molecularly characterized resistance mechanisms and genotypes/epidemiological clones, in females with uncomplicated urinary tract infections: results from two global, pivotal, phase 3 trials (EAGLE-2 and EAGLE-3).

Article

作者: Breton, John ; Sheets, Amanda J ; Scangarella-Oman, Nicole E ; Brown, Derrek ; Kasapidis, Cara ; Butler, Deborah L

Gepotidacin, a novel, bactericidal, first-in-class triazaacenaphthylene antibacterial, was noninferior to nitrofurantoin in two pivotal trials (EAGLE-2 and EAGLE-3) in females with uncomplicated urinary tract infections (uUTIs). Using pooled data, gepotidacin in vitro activity and clinical efficacy were evaluated for subsets of molecularly characterized isolates in the microbiological Intent-to-Treat population. The subsets of isolates were characterized based on phenotypic/MIC criteria; all microbiological failure isolates were also characterized. Of 1,159 Escherichia coli isolates, 30% harbored quinolone resistance-determining region (QRDR) mutations; most prevalent was gyrA S83L, D87N (27%). Extended-spectrum β-lactamases (ESBLs) were detected in 13% of E. coli isolates. For 114 Klebsiella pneumoniae isolates, 22% were plasmid-mediated quinolone resistance (PMQR) gene-positive, 11% had QRDR mutations, and 12% had ESBLs. Among 67 Proteus mirabilis isolates, 21% harbored QRDR mutations. Gepotidacin MIC₉₀ values ranged from 1 to 32 µg/mL against qualifying Enterobacterales uropathogens and genotypic subcategories, with no isolates considered resistant to gepotidacin. For all genotypic subcategories, gepotidacin MIC₉₀ values were similar (i.e., lower, equal to, or 1-dilution higher) compared with the overall species (4 µg/mL), with the exception of E. coli isolates with the PMQR qnrS1 gene (16 µg/mL); all were gepotidacin-susceptible. For the majority of uropathogens, including those with genotypes likely to cause resistance to standard uUTI therapies, success rates for gepotidacin were similar across genotypic subcategories for each species. These data show gepotidacin's efficacy and in vitro activity against a wide range of uropathogen genotypes. Additionally, these pooled results provide a robust, contemporary data set and insight into current genotypic mechanisms of resistance.CLINICAL TRIALSThis study is registered with ClinicalTrials.gov as NCT04020341 and NCT04187144.

2025-08-01·ANNALS OF INTERNAL MEDICINE

In urogenital gonorrhea, gepotidacin was noninferior to ceftriaxone + azithromycin for microbiological success

Article

作者: Glatt, Aaron E. ; Brennan, Keith ; Anaekwe, Adaeze

CLINICAL IMPACT RATINGS:

GIM/FP/GP: [Formula: see text] Infectious Disease: [Formula: see text].

103

项与 Gepotidacin 相关的新闻（医药）

2025-09-03

·PMLiVE

UK’s first new type of antibiotic for UTIs in nearly 30 years approved by MHRA

Gepotidacin (Blujepa) has been approved by the Medicines and Healthcare products Regulatory Agency (MHRA) for use by women and girls from 12 years of age, with a weight of at least 40kg. The new antibiotic is an oral pill that can be used to treat uncomplicated urinary tract infections (UTIs). It is effective against many drug-resistant infections, including E. coli, using an active ingredient that targets and blocks two enzymes that bacteria need to replicate and multiply. This type of UTI affects around 50% of women in the UK and is the most common bacterial infection in women. With drug-resistant bacteria increasing, new treatment options are critical in preventing treatment failure and complications, including sepsis or permanent kidney damage. Julian Beach, MHRA Interim Executive Director, Healthcare Quality and Access, said: “As the first new type of oral antibiotic to treat uncomplicated UTIs to be approved in nearly three decades, gepotidacin provides a new treatment option for women facing urinary tract infections that can severely impact daily life. “The antibiotic’s targeted mechanism of action makes it more difficult for bacteria to develop treatment resistance – a crucial factor as drug-resistant bacteria are increasingly on the rise globally.” Results from two multicentre, randomised, active-controlled phase 3 trials were used as evidence to support the new drug approval. In the trials, 1,572 participants were given gepotidacin and 1,564 received nitrofurantoin, the current treatment for uncomplicated UTIs. In both trials, gepotidacin was shown to be at least as effective as nitrofurantoin, with consistent results across patient groups, including those with drug-resistant bacteria and recurrent infections.

临床3期临床结果上市批准合格传染病产品

2025-09-02

·医药健闻

蔡司中国客户体验中心在上海焕新启用；万东医疗北京研发智造基地落成；飞利浦前中国区总裁履新 | 日报

全球医疗行业每日重点资讯文 | 苏丁企业动态蔡司9月1日在上海揭幕焕然一新的蔡司中国客户体验中心，标志着该中心自2015年启动、2019年首次升级后的又一里程碑。此次焕新升级覆盖医疗技术、半导体制造技术、研究显微镜解决方案、工业质量解决方案、消费品光学等所有业务板块。其中，研究显微镜解决方案事业部展示了全线产品，工业质量解决方案事业部则设立了新能源全链路检测专区，系统呈现全线多元创新业务生态。焕新后的中心面积由最初的700多平方米扩展至2100平方米，实现了在空间规模、功能配置与协同能力的全方位升级。私募股权公司对沃博联(Walgreens Boots Alliance)的收购交易已完成，这家连锁药店的上市公司身份正式终结。沃博联宣布，前史泰博(Staples)Mike Motz将出任新任首席执行官，接替Tim Wentworth。今年3月，沃博联宣布同意被Sycamore Partners收购，交易估值约100亿美元。上月，该公司股东已批准此项交易。因美纳（Illumina）宣布任命施宁乐(Nilesh Shah) 为亚太、中东及非洲（AMEA）区域负责人，任命即时生效。Nilesh将常驻新加坡，接替此前兼任AMEA临时负责人的Bas Verhoef，后者将继续担任欧洲区域负责人。施宁乐在医疗器械领域拥有超过25年的工作与管理经验，曾在强生、GE医疗、福迪威、德尔格和西施医药包装等大型企业担任领导职务。捷迈邦美（Zimmer Biomet）宣布任命Jonathan M. Vigdorchik医学博士为首席医疗技术顾问，专注于成人重建与髋关节植入领域。同时任命Anand M. Murthi医学博士为首席医疗顾问，负责肩部、运动医学、四肢及创伤（S.E.T.）领域。作为战略顾问，他们将凭借丰富的临床经验，分别在其专业领域指导公司新产品研发管线及产品组合战略，并推动捷迈邦美医疗教育项目的深化发展。拜耳将向墨西哥东部的奥里萨巴-伊斯塔佐基特兰工厂注入8亿墨西哥比索（4300万美元）来增强其产能。根据该项目，拜耳将微调其活性药物成分的生产，开发新的无菌激素注射剂系列，并对现场的基础设施、系统和实验室进行升级。此前，该公司宣布将在未来五年内在墨西哥投资30亿墨西哥比索，重点是扩大、现代化和翻新当地生产基地。罗氏考虑了12个高科技集群，然后确定了熟悉的制药制造地点——北卡罗来纳州霍利斯普林斯——来建造新的肥胖药物生产设施。罗氏子公司基因泰克（Genentech）耗资7亿美元的工厂破土动工，该工厂预计将于2029年投入运营。这是罗氏未来五年在美国投资500亿美元以支持其制造和研发业务的计划的一部分。美的医疗旗下万东医疗北京研发智造基地正式落成启动。新基地将聚焦高端医疗影像设备智造，通过智能化、数字化手段，实现产品品质与生产效能的双重提升。万东已形成北京、沈阳、苏州、上海四大研发基地协同创新的格局。百洋医药发布董事会换届选举公告，宣布提名原飞利浦（中国）投资有限公司总裁HO KWOK WAI ANDY（何国伟）先生为公司独立董事。何国伟，加拿大国籍，具有中国大陆及香港永久居留权，曾在IBM、荷兰皇家飞利浦任职。睿智医药（ChemPartner）波士顿研发中心开幕。新的研发基地位于马萨诸塞州沃特敦，将于9月10日开始运营，为北美及其他地区的生物制药客户提供发现和临床前服务。该研究中心提供生物制剂发现、药理学和DMPK服务，支持从早期发现到IND支持阶段的体外和体内研究。该设施占地约12,000平方英尺，将拥有一支经验丰富的科学团队。设备安装正在进行中，初步项目计划于今年秋天启动。眼科医疗器械企业思埃然医疗（Sierra Medical）宣布完成新一轮超亿元融资。本轮融资由千骥资本、顺为资本联合领投，老股东博行资本、弘晖基金持续加码。本轮融资资金将主要用于公司首款自主研发的超乳玻切一体机产品线的深度研发推进。深圳虹信生物科技有限公司宣布完成近亿元Pre-A+轮融资。本轮融资由IDG资本领投，高瓴创投及元生创投跟投，老股东恒晔科投继续追加投资。本轮融资将用于核心产品HN2301的IND申报及IIT临床研究。诺唯赞与艺妙神州签署《细胞治疗合作项目合作开发协议》，拟共同设立一家生物制药公司，注册资本为人民币4000万元，双方各持股50%。合资公司将在细胞治疗领域开展投资合作项目，旨在科技创新赋能阿尔兹海默症筛查、预防、治疗的全周期防治。康众医疗与上海孛璞半导体技术有限公司正式签署战略合作协议。双方将围绕光传感与全光电路交换（OCS）技术在AI医疗领域的研发与产业化展开深度合作，共同推动新一代医疗数据采集与算力网络技术的创新与规模化落地。产业动态诺和诺德宣布与Replicate Bioscience达成一项为期多年的研发合作协议，交易总额或达5.5亿美元，将借助新型RNA技术攻克心脏代谢疾病难题。此次合作的核心在于诺和诺德将获得Replicate技术平台的使用权，针对心脏代谢疾病靶点开展研究。强生公司表示，由于一项中期试验的结果没有显示出足够的疗效，该公司决定不再继续开发针对一种关节炎患者的联合用药。该公司正在研究将其药物尼泊卡利单抗与一种抗肿瘤坏死因子α治疗相结合，后者有助于阻止炎症。在中期试验中，对于难以治疗的类风湿性关节炎患者，联合疗法未能显示出比单独使用抗肿瘤坏死因子α疗法更显著的疗效。赛诺菲宣布美国FDA已批准其BTK抑制剂Wayrilz (Rilzabrutinib) 上市，用于治疗免疫性血小板减少症。这也是全球首个获批治疗免疫性血小板减少症的BTK抑制剂。英国药品和健康产品管理局宣布，已批准由葛兰素史克公司研发的Blujepa用于治疗12岁及以上、体重至少40公斤女性的单纯性尿路感染，该药物为新型口服抗生素片剂。卫材和渤健宣布，美国FDA已批准仑卡奈单抗（乐意保）皮下自动注射剂型（IQLIKTM）用于早期阿尔茨海默病（AD）维持治疗，并将于2025年10月6日在美国上市。昂利康与亚飞（上海）生物医药科技有限公司、上海亲合力生物医药科技股份有限公司签署《战略合作协议之授权许可协议》，公司将获得IMD-1005药物分子在中国（包括中国大陆地区、香港特别行政区、澳门特别行政区以及中国台湾地区）的研发、生产、商业化独家权益。公司将分阶段向亚飞生物、亲合力合计支付1.5亿元人民币首付款，以及向亲合力支付最高不超过6.2亿元人民币的研发、销售里程碑付款。ALK-N002/IMD-1005是一种全球创新的肿瘤微环境激活型的IgG1亚型的靶向CD47的遮罩型抗体药物。再鼎医药宣布，香港特别行政区政府卫生署已批准TIVDAK（维替索妥尤单抗）在香港地区用于治疗化疗期间或之后出现疾病进展的复发性或转移性宫颈癌成年患者。参天公司宣布旗下他氟噻吗滴眼液泰浦康（TAPCOM）在中国正式上市。泰浦康是中国首个含有青光眼一线治疗药物PG衍生物且不含防腐剂的原研眼用复方制剂，用于降低开角型青光眼或高眼压症患者的眼压（IOP）。恒瑞医药收到国家药品监督管理局的通知，附条件批准公司自主研发的1类创新药泽美妥司他片（SHR2554片）上市，用于既往接受过至少1线系统性治疗的复发或难治外周T细胞淋巴瘤（R/RPTCL）成人患者。北京新增10项医疗服务项目，涉及常见病、多发病的精准诊断和先进治疗。这些新项目将在多家医院陆续开展。此次新增项目包括，“诺如病毒抗原测定”项目、“医学3D建模（神经血管）”项目、多项肿瘤精准诊断项目、“病原宏基因组测序”项目等。中国研究团队25日在英国学术期刊《自然-医学》在线发表论文，报告世界首个将基因编辑猪肺成功移植到脑死亡人体内的案例。该供体猪经过6处基因编辑，以降低其器官移植到人体后的免疫风险。手术后，呼吸、血液、影像等监测数据显示，移植肺维持通气与气体交换功能长达9天，其间未发生超急性排异反应，同步病原学监测也未发现活跃感染迹象。联系美通社 +86-10-5953 9500 info@prnasia.com

并购高管变更

2025-08-28

·ETPharma

British regulator approves GSK's Blujepa drug for UTI in women and girls

Bengaluru: Britain's medicines regulator said on Thursday it approved GSK's Blujepa, an antibiotic pill, to treat uncomplicated urinary tract infections (UTIs) in females aged 12 and older. The active ingredient in Blujepa, chemically known as gepotidacin , targets and blocks two enzymes that bacteria need to replicate and multiply, making it work against many drug-resistant infections such as E. coli, the Medicines and Healthcare products Regulatory Agency (MHRA) said in a statement. It said the approval for the oral medication is for females who weigh at least 40kg (88lbs). GSK did not immediately respond to a Reuters request for a comment regarding the date of launch and pricing. The U.S. Food and Drug Administration in March approved the drug, which was expected to be launched in the U.S. in the second half of this year. GSK is banking on new drugs in its infectious diseases portfolio, including its recently launched respiratory syncytial virus vaccine, to make up for lost revenues from its best-selling medicines and looming patent losses for its HIV treatments. (Reporting by Angela Christy in Bengaluru; Editing by Himani Sarkar and Leslie Adler)

上市批准

100 项与 Gepotidacin 相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D10878	Gepotidacin	-	DB12134

研发状态

批准上市

10 条最早获批的记录,

登录

后查看更多信息

适应症	国家/地区	公司	日期
细菌感染	美国	GlaxoSmithKline LLC	2025-03-25
泌尿道感染	美国	GlaxoSmithKline LLC	2025-03-25

未上市

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
淋菌性尿道炎	临床3期	美国	GSK Plc	2019-10-21
淋菌性尿道炎	临床3期	澳大利亚	GSK Plc	2019-10-21
淋菌性尿道炎	临床3期	德国	GSK Plc	2019-10-21
淋菌性尿道炎	临床3期	墨西哥	GSK Plc	2019-10-21
淋菌性尿道炎	临床3期	西班牙	GSK Plc	2019-10-21
淋菌性尿道炎	临床3期	英国	GSK Plc	2019-10-21
急性膀胱炎	临床3期	美国	GSK Plc	2019-10-17
急性膀胱炎	临床3期	保加利亚	GSK Plc	2019-10-17
急性膀胱炎	临床3期	捷克	GSK Plc	2019-10-17
急性膀胱炎	临床3期	德国	GSK Plc	2019-10-17

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT04187144 \| NCT04020341 (FDA_CDER) 人工标引	临床3期	细菌感染 \| 泌尿道感染	-	BLUJEPA (Trial 1)	願糧齋夢鑰範築壓夢製(繭願鹽糧觸齋繭壓淵醖) = 糧夢遞構鹹衊選選廠構醖鏇糧膚襯艱鬱窪壓鬱 (艱願選構遞憲齋鑰壓願 ) 更多	积极	2025-03-25
				Nitrofurantoin (Trial 1)	願糧齋夢鑰範築壓夢製(繭願鹽糧觸齋繭壓淵醖) = 選築壓構選願繭鬱窪蓋醖鏇糧膚襯艱鬱窪壓鬱 (艱願選構遞憲齋鑰壓願 ) 更多
NCT05630833 (EAGLE-J, CTgov)	临床3期	泌尿道感染 \| 急性膀胱炎 \| 脓尿	380	Gepotidacin (Gepotidacin)	鏇醖遞遞夢餘憲廠襯築 = 夢襯醖製蓋製獵餘艱觸觸艱艱餘膚艱鬱窪鹽鏇 (築鏇範襯糧網襯蓋鏇餘, 衊衊範憲鑰齋鹹築鬱鑰 ~ 積遞蓋選顧鹹鏇醖網蓋) 更多	-	2025-03-17
				Nitrofurantoin (Nitrofurantoin)	壓簾選蓋獵醖糧齋簾遞 = 製鹽遞鹹範繭憲蓋範顧獵憲築繭製艱廠範顧鏇 (淵窪繭願鑰遞網鏇鏇夢, 窪蓋壓製夢醖蓋艱簾製 ~ 襯觸積鏇範鹽構衊觸糧) 更多
NCT04010539 (EAGLE-1, NEWS) 人工标引	临床3期	淋病	600	gepotidacin (oral, two doses of 3,000mg)	廠鬱糧構壓壓壓網廠壓(夢獵艱鑰衊糧淵醖積淵) = 齋鏇範願顧壓齋蓋夢獵構鑰膚夢繭淵獵鏇蓋範 (觸觸範餘簾簾膚願範構 )	积极	2024-04-18
				intramuscular (IM) ceftriaxone (500mg) plus oral azithromycin (1,000mg) combined therapy	廠鬱糧構壓壓壓網廠壓(夢獵艱鑰衊糧淵醖積淵) = 網廠憲鑰衊製鏇窪網構構鑰膚夢繭淵獵鏇蓋範 (觸觸範餘簾簾膚願範構 )
NCT04010539 (EAGLE-1, NEWS) 人工标引	临床3期	淋病	-	Gepotidacin	願築糧襯鏇壓鬱窪窪顧(積簾壓餘餘築遞觸醖壓) = proving to be as effective as an existing treatment for the infection. 繭範壓鏇遞壓窪壓築觸 (鏇範餘醖廠膚鬱廠築衊 ) 达到	非劣	2024-02-26
				Ceftriaxone+Azithromycin
NCT04187144 (EAGLE-3, CTgov)	临床3期	泌尿道感染 \| 急性膀胱炎 \| 脓尿	1,606	Placebo matching nitrofurantoin+Gepotidacin (Gepotidacin)	膚夢衊壓憲鹽餘齋壓醖 = 築簾襯築鏇襯鑰蓋廠遞顧鑰夢醖廠艱築鹹齋鹽 (鬱積餘憲廠範窪壓網餘, 網淵選廠廠襯廠築繭遞 ~ 淵顧蓋鑰製觸壓窪顧簾) 更多	-	2023-07-18
				Placebo matching gepotidacin+Nitrofurantoin (Nitrofurantoin)	膚夢衊壓憲鹽餘齋壓醖 = 簾壓壓選鹹構範積繭鏇顧鑰夢醖廠艱築鹹齋鹽 (鬱積餘憲廠範窪壓網餘, 製蓋艱築廠構鬱鏇範鹽 ~ 壓鹽獵鏇網衊鹹窪鑰觸) 更多
NCT04020341 (CTgov)	临床3期	泌尿道感染 \| 急性膀胱炎 \| 脓尿	1,531	Placebo matching nitrofurantoin+Gepotidacin (Gepotidacin)	糧繭醖選艱選淵願繭範 = 築鬱齋願網顧製齋襯夢蓋遞觸構積憲繭製選遞 (蓋齋蓋餘襯淵製鹽齋積, 淵獵夢築窪齋襯糧淵觸 ~ 蓋蓋選餘膚齋醖憲夢繭) 更多	-	2023-06-22
				Placebo matching gepotidacin+Nitrofurantoin (Nitrofurantoin)	糧繭醖選艱選淵願繭範 = 積蓋艱願築遞夢築艱簾蓋遞觸構積憲繭製選遞 (蓋齋蓋餘襯淵製鹽齋積, 淵齋簾鹹膚艱選範範範 ~ 壓鏇製製製窪構範鏇網) 更多
NCT02294682 (Pubmed \| Sex Transm Infect)	临床3期	淋病	-	Gepotidacin 3000 mg	鏇淵壓獵築憲獵選觸窪(襯製壓醖製鏇鹹膚齋鏇) = 構夢膚膚鏇憲夢醖衊網憲鹽網築憲獵鹹艱衊壓 (鑰廠製衊憲築鏇網顧餘 )	-	2022-11-21
NCT04187144 (EAGLE-3, Corporate Publications) 人工标引	临床3期	泌尿道感染	2,500	Gepotidacin	選遞衊製顧蓋觸築衊窪(醖鹹鹹鑰艱觸膚齋製遞) = met the primary efficacy endpoint 鹹廠築製憲築窪積製繭 (鏇糧夢鬱選衊膚顧淵積 ) 达到	非劣	2022-11-03
				Nitrofurantoin
NCT04079790 (CTgov)	临床1期	细菌感染	34	Gepotidacin (Part 1: Gepotidacin 1500 mg)	壓遞壓鹽遞窪鬱選壓鬱(願夢醖膚鏇繭願遞糧鹽) = 壓夢夢繭衊願鹹選夢製顧齋鬱網鹹簾獵夢繭網 (膚鬱遞構範襯膚憲遞簾, 17.6) 更多	-	2020-09-04
				Gepotidacin (Part 1: Gepotidacin 3000 mg 12 Hour Interval)	築範簾蓋膚獵衊鹹窪願(範製齋憲選鬱積鏇醖膚) = 壓糧鑰醖齋獵觸窪網廠網壓遞壓壓鬱積窪蓋蓋 (網製鬱繭網齋鏇窪築憲, 22.6) 更多
NCT02729038 (Pubmed)	临床1期	肾功能不全	-	Gepotidacin (Subjects with normal renal function)	廠壓窪簾鹹壓膚繭窪蓋(衊憲夢構範餘網鹽簾鑰) = 夢艱蓋廠簾齋襯襯鹹觸鹽鬱獵築鑰蓋鹽齋築窪 (淵鬱鹹艱顧積衊觸衊淵 )	-	2020-07-01
				Gepotidacin (Subjects with moderate renal impairment)	廠壓窪簾鹹壓膚繭窪蓋(衊憲夢構範餘網鹽簾鑰) = 窪糧夢蓋淵衊窪積廠顧鹽鬱獵築鑰蓋鹽齋築窪 (淵鬱鹹艱顧積衊觸衊淵 )